Bluejay Diagnostics closed at $2.21 on Nov 3, down 73.94%, within 2.3% of its 52-week closing low. Volume of 446.3K shares was 1.00× its 20-day average (close to normal).
Split-adjusted performance: -27.4% over one month, -71.4% over six months, -93.0% over one year.
Short interest was 144.4K shares at the Oct 15 settlement (3.6% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −9.7%, revenue growth +8.9%, net margin −8.2%, P/E 28.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BJDXBluejay Diagnostics | $2.21 | −73.94% | −71.4% | — | — | — | $2.5M | |
| ADGMAdagio Medical Holdings | $0.0862 | −0.92% | −91.2% | — | — | — | $2.4M | Compare |
| XAIRBeyond Air | $2.32 | +4.98% | −80.0% | +0.5% | −448.8% | — | $2.3M | Compare |
| IVFINVO Fertility | $1.94 | +6.01% | −74.3% | +16.7% | 40.9% | — | $2.2M | Compare |
| VVOSVivos Therapeutics | $0.1098 | +1.39% | −84.5% | +34.9% | −106.4% | — | $2.2M | Compare |
| NXGLNexGel | $4.48 | +18.21% | −62.1% | +27.8% | −98.6% | — | $2.2M | Compare |
| AMIXAutonomix Medical | $1.66 | −1.19% | −79.1% | — | — | — | $3.3M | Compare |
| CODXCo-Diagnostics | $0.3800 | +7.56% | — | +2.0% | −3782.4% | — | $3.4M | Compare |
| AEMDAETHLON MEDICAL | $5.80 | +9.64% | −50.8% | — | — | — | $4.1M | Compare |
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
